Dopaminergic effects after chronic treatment with nandrolone visualized in rat brain by positron emission tomography

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 7-8, 2002, Pages 1303-1308

  Kindlundh, Anna M S ^a   Bergström, Mats ^b   Monazzam, Azita ^b   Hallberg, Mathias ^a   Blomqvist, Gunnar ^b   Långström, Bengt ^b   Nyberg, Fred ^a  

^a Div Biol Res Drug Dependence   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

11C (+) SCH23390; 11C FE CIT; 11C raclopride; Anabolic androgenic steroids; Dopamine receptors; Dopamine transporter; Nandrolone; Positron emission tomography

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; NANDROLONE DECANOATE; RACLOPRIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; DRUG BINDING; DRUG EFFECT; IN VIVO STUDY; LONG TERM CARE; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT; REGULATORY MECHANISM;

ANABOLIC AGENTS; ANIMALS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NANDROLONE; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED; UP-REGULATION;

EID: 0036889685     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(02)00293-2     Document Type: Article

References (45)

1. Amara S.G., Kuhar M.J. Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16:1993;73-93.
2. Bahrke M.S., Yesalis C.E., Kopstein A.N., Stephens J.A. Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Med. 29:2000;397-405.
3. Brower K.J., Blow F.C., Young J.P., Hill E.M. Symptoms and correlates of anabolic-androgenic steroid dependence. Br. J. Addict. 86:1991;759-768.
4. Chen N., Reith M.E. Structure and function of the dopamine transporter. Eur. J. Pharmacol. 405:2000;329-339.
5. Clark A.S., Mitre M.C., Brinck-Johnsen T. Anabolic-androgenic steroid and adrenal steroid effects on hippocampal plasticity. Brain Res. 679:1995;64-71.
6. Copeland J., Peters R., Dillon P. Anabolic-androgenic steroid use disorders among a sample of Australian competitive and recreational users. Drug Alcohol Depend. 60:2000;91-96.
7. Di Chiara G., Tanda G., Bassareo V., Pontieri F., Acquas E., Fenu S., Cadoni C., Carboni E. Drug addiction as a disorder of associative learning. Role of nucleus accumbens shell/extended amygdala dopamine. Ann. N. Y. Acad. Sci. 877:1999;461-485.
8. Everitt B.J., Parkinson J.A., Olmstead M.C., Arroyo M., Robledo P., Robbins T.W. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann. N. Y. Acad. Sci. 877:1999;412-438.
9. Farde L. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology (Berlin). 92:1987;278-284.
10. Galligani N., Renck A., Hansen S. Personality profile of men using anabolic androgenic steroids. Horm. Behav. 30:1996;170-175.
11. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J. Jr., Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
12. Giros B., Caron M.G. Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 14:1993;43-49.
13. Hallberg M., Johansson P., Kindlundh A.M., Nyberg F. Anabolic-androgenic steroids affect the content of substance P and substance P(1-7) in the rat brain. Peptides. 21:2000;845-852.
14. Halldin C., Farde L., Lundkvist C., Ginovart N., Nakashima Y., Karlsson P., Swahn C.G. [11C]beta-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. Synapse. 22:1996;386-390.
15. Handelsman D.J., Gupta L. Prevalence and risk factors for anabolic-androgenic steroid abuse in Australian high school students. Int. J. Androl. 20:1997;159-164.
16. Hartvig P., Bergstrom M., Langstrom B. Use of positron emission tomography in analysing receptor function in vivo. Toxicol. Lett. 120:2001;243-251.
17. Heimer L., Zaborszky L., Zahm D.S., Alheid G.F. The ventral striatopallidothalamic projection: I. The striatopallidal link originating in the striatal parts of the olfactory tubercle. J. Comp. Neurol. 255:1987;571-591.
18. Hitri A., Little K.Y., Ellinwood E.H. Jr. Effect of cocaine on dopamine transporter receptors depends on routes of chronic cocaine administration. Neuropsychopharmacology. 14:1996;205-210.
19. Isovich E., Mijnster M.J., Flugge G., Fuchs E. Chronic psychosocial stress reduces the density of dopamine transporters. Eur. J. Neurosci. 12:2000;1071-1078.
20. Jaber M., Jones S., Giros B., Caron M.G. The dopamine transporter: a crucial component regulating dopamine transmission. Mov. Disord. 12:1997;629-633.
21. Johansson P., Hallberg M., Kindlundh A., Nyberg F. The effect on opioid peptides in the rat brain, after chronic treatment with the anabolic androgenic steroid, nandrolone decanoate. Brain Res. Bull. 51:2000;413-418.
22. Johansson P., Lindqvist A., Nyberg F., Fahlke C. Anabolic androgenic steroids affects alcohol intake, defensive behaviors and brain opioid peptides in the rat. Pharmacol. Biochem. Behav. 67:2000;271-279.
23. Kindlundh A.M., Isacson D.G., Berglund L., Nyberg F. Doping among high school students in Uppsala, Sweden: a presentation of the attitudes, distribution, side effects, and extent of use. (letter) Scand. J. Soc. Med. 26:1998;71-74.
24. Kindlundh A.M., Isacson D.G., Berglund L., Nyberg F. Factors associated with adolescent use of doping agents: anabolic-androgenic steroids. Addiction. 94:1999;543-553.
25. Kindlundh A., Lindblom J., Bergstrom L., Wikberg J., Nyberg F. The anabolic-androgenic steroid nandrolone decanoate affects the density of dopamine receptors in the male rat brain. Eur. J. Neurosci. 13:2001;291-296.
26. Kindlundh A.M., Hagekull B., Isacson D.G., Nyberg F. Adolescent use of anabolic-androgenic steroids and relations to self-reports of social, personality and health aspects. Eur. J. Public Health. 11:2001;322-328.
27. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13:1992;177-184.
28. Kuhar M.J., Ritz M.C., Boja J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 14:1991;299-302.
29. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. Neuroimage. 4:1996;153-158.
30. Le Greves P., Huang W., Johansson P., Thornwall M., Zhou Q., Nyberg F. Effects of an anabolic-androgenic steroid on the regulation of the NMDA receptor NR1, NR2A and NR2B subunit mRNAs in brain regions of the male rat. Neurosci. Lett. 226:1997;61-64.
31. Lu X.Y., Ghasemzadeh M.B., Kalivas P.W. Expression of D1 receptor, D2 receptor, substance P and enkephalin messenger RNAs in the neurons projecting from the nucleus accumbens. Neuroscience. 82:1998;767-780.
32. Lukas S.E. CNS effects and abuse liability of anabolic-androgenic steroids. Annu. Rev. Pharmacol. Toxicol. 36:1996;333-357.
33. Meiergerd S.M., Patterson T.A., Schenk J.O. D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J. Neurochem. 61:1993;764-767.
34. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 78:1998;189-225.
35. Nilsson S. Androgenic anabolic steroid use among male adolescents in Falkenberg. Eur. J. Clin. Pharmacol. 48:1995;9-11.
36. Pontieri F.E., Tanda G., Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc. Natl. Acad. Sci. U. S. A. 92:1995;12304-12308.
37. Pope H.G. Jr., Katz D.L. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch. Gen. Psychiatry. 51:1994;375-382.
38. Reith M.E., Xu C., Chen N.H. Pharmacology and regulation of the neuronal dopamine transporter. Eur. J. Pharmacol. 324:1997;1-10.
39. Schlussman S.D., Zhou Y., Johansson P., Kiuru A., Ho A., Nyberg F., Kreek M.J. Effects of the androgenic anabolic steroid, nandrolone decanoate, on adrenocorticotropin hormone, corticosterone and proopiomelanocortin, corticotropin releasing factor (CRF) and CRF receptor1 mRNA levels in the hypothalamus, pituitary and amygdala of the rat. Neurosci. Lett. 284:2000;190-194.
40. Su T.-P., Pagliaro M., Schmidt P.J., Pickar D., Wolkowitz O., Rubinow D.R. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA, J. Am. Med. Assoc. 269:1993;2760-2764.
41. Tanner S.M., Miller D.W., Alongi C. Anabolic steroid use by adolescents: prevalence, motives, and knowledge of risks. Clin. J. Sport Med. 5:1995;108-115.
42. Thiblin I., Finn A., Ross S.B., Stenfors C. Increased dopaminergic and 5-hydroxytryptaminergic activities in male rat brain following long-term treatment with anabolic androgenic steroids. Br. J. Pharmacol. 126:1999;1301-1306.
43. Wichstrom L., Pedersen W. Use of anabolic-androgenic steroids in adolescence: winning, looking good or being bad? J. Stud. Alcohol. 62:2001;5-13.
44. Williamson D.J., Young A.H. Psychiatric effects of androgenic and anabolic-androgenic steroid abuse in men: a brief review of the literature. J. Psychopharmacol. 6:1992;20-26.
45. Yesalis C.E., Bahrke M.S. Anabolic-androgenic steroids. Current issues. Sports Med. 19:1995;326-340.